Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19331709 | 1.00 | TRPA1 (0.34) | TRPA1ALDH1A1RIPK1HTTATM | |
| SCHEMBL17006154 | 1.00 | TRPA1 (0.34) | TRPA1ALDH1A1RIPK1HTTATM | |
| SCHEMBL8175900 | 0.95 | TRPA1 (0.35) | TRPA1ALDH1A1RIPK1HTTATM | |
| SCHEMBL4455719 | 0.95 | TRPA1 (0.35) | TRPA1ALDH1A1RIPK1HTTATM | |
| SCHEMBL19331751 | 0.91 | ALDH1A1 (0.33) | ALDH1A1RRM1TACR3CYP3A4 | |
| SCHEMBL19331696 | 0.91 | ALDH1A1 (0.32) | ALDH1A1RRM1TACR3CYP3A4SMN1; SMN2 | |
| SCHEMBL14564989 | 0.89 | TRPA1 (0.40) | TRPA1RIPK1HTTKCNH3CYP3A4 | |
| SCHEMBL8391322 | 0.89 | TRPA1 (0.40) | TRPA1RIPK1HTTKCNH3CYP3A4 | |
| SCHEMBL27032153 | 0.89 | TRPA1 (0.40) | TRPA1RIPK1HTTKCNH3CYP3A4 | |
| SCHEMBL25764380 | 0.88 | ALDH1A1 (0.31) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2025-01-30 | — | — | US | disclosed |
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2024-02-08 | — | — | US | disclosed |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-07-04 | — | — | US | disclosed |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | NEW YORK MEDICAL COLLEGE | 2020-01-30 | — | — | US | disclosed |
| WO-2017156164-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-14 | — | — | WO | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041831-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | TRPA1 524/4885ALDH1A1 2622/4885RIPK1 1470/4885 |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | TYMP, EIF2AK2, MAVS | TRPA1 4809/4885ALDH1A1 3005/4885RIPK1 441/4885 |
| US-20250032453-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | TRPA1 524/4885ALDH1A1 2622/4885RIPK1 1470/4885 |
| US-20200030291-A1 | 20-HETE RECEPTOR (GPR75) ANTAGONISTS AND METHODS OF USE | GPR55, GPR65, GPR35 | TRPA1 524/4885ALDH1A1 2622/4885RIPK1 1470/4885 |
| US-11690825-B2 | 20-HETE receptor (GPR75) antagonists and methods of use | GPR55, GPR65, GPR35 | TRPA1 524/4885ALDH1A1 2622/4885RIPK1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.